Abstract: Objective To investigate the efficacy and toxicity of bevacizumab combined with FOLFOX regimen or FOLFIRI regimen for patients with metastatic colorectal cancer（mCRC） as first- or second-line treatment. Methods Fifty-seven patients with mCRC treated by bevacizumab combined with FOLFOX or FOLFIRI in the PLA General Hospital from December 2005 to August 2012 were analyzed retrospectively with their overall response rate（RR），disease control rate（DCR），progressionfree survival（PFS），and overall survival（OS）. The tumor responses were assessed by response evaluation criteria in solid tumors guidelines（RECIST） version 1.1. The adverse reation was evaluated by common terminology criteria for adverse events version 3.0. The survival analysis was used by Kaplan-Meier method. Results Of 57 patients with mCRC，19（33.3％） patients achieved partial response（PR）and 28 patients（49.2％） had stable disease（SD），exhibited an RR of 33.3％，and a DCR of 82.5％. Stratification analysis by first- and second-line treatment or different chemotherapy of bevacizumab combined FOLFOX regimen or FOLFIRI regimen，there were no statistical significance in RR and DCR（P＞0.05）. The median PFS and OS of 57 patients were 8.83 months and 14.80 months, respectively. Stratification analysis by first- and second-line treatment or different chemotherapy of bevacizumab combined FOLFOX regimen or FOLFIRI regimen，there were no statistical significance in median PFS and OS（P＞005）.The main side effects were leukocytopenia，leukocytopenia and nausea and vomiting. The adverse events related to bevacizumab included hypertension，proteinuria and epistaxis，which were mostly in grade1-2 and alleviated by drug treatment. Conclusion Bevacizumab combined with FOLFOX regimen or FOLFIRI regimen is effective and well tolerated in patients with metastatic colorectal cancer.